Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05301192 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Angiotensin-(1-7) Cardiovascular Effects in Aging

StatusTerminated
PhaseEarly Phase 1
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Trial terminated Sponsor's reason: Funding terminated Show 5 more changesShow less
    • Final enrollment: 4 participants (planned 26)
    • Primary completion date changed from estimate of Dec 2026 to Jun 10, 2024
    • Eligibility criteria expanded, about 7 words
    • Secondary endpoints: details revised at 1 of 8 entries
    • Site details revised
  2. Primary and study completion dates: Dec 2025 to Dec 2026v12
  3. Re-verified, no change to tracked fieldsv11
  4. Primary completion date: Jun 1, 2024 to Dec 2025
    • Study completion date: Dec 1, 2024 to Dec 2025
    • Site contact updated
    v10
  5. 2 versions Re-verified since Nov 2, 2023, no change to tracked fieldsv8-v9
Show 6 earlier versionsHide 6 earlier versions
  1. Start date: Oct 5, 2022 to Dec 9, 2022
    • Primary completion date: Sep 30, 2024 to Jun 1, 2024
    • Study completion date: Sep 30, 2024 to Dec 1, 2024
    • Collaborators expanded, about 7 words
    v7
  2. Re-verified, no change to tracked fieldsv6
  3. Trial status: Not Yet Recruiting to Recruiting
    • Primary and study completion dates: May 31, 2024 to Sep 30, 2024
    • Start date changed from estimate of Oct 1, 2022 to Oct 5, 2022
    • Site details revised
    v5
  4. Start date: Jul 1, 2022 to Oct 1, 2022v4
  5. Start date: Jun 1, 2022 to Jul 1, 2022v3
  6. Eligibility criteria expanded, about 28 wordsv2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Aging is an independent risk factor for developing hypertension and cardiovascular disease; however, the mechanisms underlying age-related cardiovascular disease remain poorly understood. One hallmark of aging is an increase in sympathetic nervous system activity, which can decrease the number and/or sensitivity of β2 adrenergic receptors to reduce dilation of blood vessels and increase blood pressure. Identifying new targets to restore vascular β2 adrenergic receptor signaling may help reduce cardiovascular risk in aging. This study will test the hypothesis that angiotensin-(1-7), a protective hormone of the renin-angiotensin system, can reduce cardiovascular sympathetic outflow and blood pressure and improve endothelial function in older healthy humans.
Trial Details
NCT Number NCT05301192
Lead Sponsor Milton S. Hershey Medical Center
Collaborators: National Heart, Lung, and Blood Institute (NHLBI)
Conditions
(from sponsor)		 Aging
Enrollment 4 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov